Goldstein is also waiting on the approval of FluMist, an inhalable flu vaccine the company is co-developing with MedImmune (nasdaq: MEDI - news - people ).
MedImmune (nasdaq: MEDI - news - people ), a biotech that sells a flu vaccine called FluMist that is given as a nose spray, can probably provide less than 2 million doses.